Group 1 - The core viewpoint of the news is that Tianji Co., Ltd. has experienced a significant decline in stock price, dropping 5.03% on September 23, with a total decrease of 20.61% over four consecutive days [1] - As of the report, Tianji's stock price is at 14.34 yuan per share, with a trading volume of 635 million yuan and a turnover rate of 8.53%, leading to a total market capitalization of 7.19 billion yuan [1] - The company, established in March 1996 and listed in May 2015, specializes in the research, production, and sales of ceramic cooking appliances and lithium hexafluorophosphate, with the latter accounting for 67.27% of its main business revenue [1] Group 2 - From the perspective of Tianji's top ten circulating shareholders, Dongfang Fund holds a position in Tianji Co., Ltd., with its Dongfang New Energy Vehicle Theme Mixed Fund maintaining 3.01 million shares, representing 0.6% of circulating shares [2] - The fund has incurred a floating loss of approximately 2.29 million yuan today and a total floating loss of 11.81 million yuan during the four-day decline [2] - The Dongfang New Energy Vehicle Theme Mixed Fund, established in December 2011, has a current scale of 7.86 billion yuan and has achieved a year-to-date return of 42.1% [2]

Core Viewpoint - Enwei Pharmaceutical has experienced a decline in stock price, with a cumulative drop of 5.48% over three consecutive days, currently trading at 33.97 CNY per share, with a market capitalization of 3.495 billion CNY [1] Company Overview - Enwei Pharmaceutical Co., Ltd. was established on May 19, 2005, and went public on September 21, 2022. The company is based in Chengdu, Sichuan Province, and focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, particularly in gynecology, pediatrics, and respiratory system medications [1] - The revenue composition of Enwei Pharmaceutical is as follows: gynecology products 46.21%, others 31.74%, cold medications 14.71%, pediatrics 6.90%, and other supplementary products 0.44% [1] Shareholder Insights - Among the top ten circulating shareholders of Enwei Pharmaceutical, the Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) reduced its holdings by 470,600 shares in the second quarter, now holding 529,400 shares, which represents 1.61% of the circulating shares. The estimated floating loss today is approximately 529,400 CNY, with a total floating loss of 1,042,900 CNY over the three-day decline [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund was established on December 25, 2014, with a current size of 2.074 billion CNY. Year-to-date returns are 21.65%, ranking 3,497 out of 8,180 in its category, while the one-year return is 44.14%, ranking 3,083 out of 7,967 [2]

Core Viewpoint - Jianyuan Trust has experienced a decline in stock price, with a cumulative drop of 6.82% over the past four days, indicating potential concerns among investors regarding the company's performance and market conditions [1][2]. Company Overview - Jianyuan Trust Co., Ltd. is located at 689 Guangdong Road, Haitong Securities Building, Huangpu District, Shanghai, and was established on September 15, 1995, with its listing date on January 28, 1994 [1]. - The company's main business includes fund trusts, wealth management trusts, public welfare trusts, investment banking, and proprietary business, with trust business accounting for 89.36% of its revenue and proprietary business for 10.64% [1]. Stock Performance - As of September 3, Jianyuan Trust's stock price is reported at 2.87 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 1.22%, leading to a total market capitalization of 28.254 billion CNY [1]. - The stock has seen a continuous decline for four consecutive days, with a drop of 3.04% on the latest trading day [1]. Shareholder Insights - Among the top ten circulating shareholders of Jianyuan Trust, a fund under Southern Fund has increased its holdings in Jianyuan Trust, acquiring an additional 8.3261 million shares, bringing its total to 58.8595 million shares, which represents 1.08% of the circulating shares [2]. - The Southern CSI 500 ETF (510500) has reported a floating loss of approximately 5.2974 million CNY today and a total floating loss of 12.3605 million CNY during the four-day decline [2]. Fund Performance - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a current scale of 113.438 billion CNY, achieving a year-to-date return of 23.14% and a one-year return of 55.04% [2]. - The fund manager, Luo Wenjie, has a tenure of 12 years and 138 days, with the fund's total asset scale at 138.999 billion CNY, achieving the best return of 141.73% and the worst return of -47.6% during his management period [2].

Group 1 - The core viewpoint of the news is that Fosa Technology's stock has experienced a decline, with a 5.01% drop on August 25, resulting in a total market value of 6.308 billion yuan and a cumulative decline of 6.14% over three consecutive days [1] - Fosa Technology, established on October 20, 2006, is located in Wuhu City, Anhui Province, and focuses on the research, production, and sales of automotive interior components, with main business revenue composition being 52.88% functional parts, 42.16% decorative parts, and 4.96% others [1] - The stock's trading volume on August 25 was 167 million yuan, with a turnover rate of 4.86% [1] Group 2 - Among the top ten circulating shareholders of Fosa Technology, Guotai Fund's Guotai Valuation Advantage Mixed Fund (LOF) A (160212) entered the list in the second quarter, holding 2.0623 million shares, accounting for 4.56% of circulating shares [2] - The Guotai Valuation Advantage Mixed Fund (LOF) A has experienced a year-to-date return of 47.71% and a one-year return of 84.08%, ranking 478 out of 8259 and 483 out of 8023 respectively [2] - The fund manager, Wang Zhaoxiang, has a cumulative tenure of 3 years and 67 days, with the fund's total asset scale at 2.123 billion yuan [2]